June 18, 2018 / 6:49 AM / 3 months ago

CORRECTED-BRIEF-NeuroVive Out-Licenses Targeted Lhon Therapy To Bridgebio Pharma

(Corrects company name in headline)

June 18 (Reuters) - NeuroVive Pharmaceutical AB:

* NEUROVIVE OUT-LICENSES TARGETED LHON THERAPY TO BRIDGEBIO PHARMA’S NEW SUBSIDIARY FORTIFY THERAPEUTICS

* LICENSING AGREEMENT FOR THIS PARTICULAR SUBSET OF NVP015 PROGRAM HAS TOTAL DEAL VALUE OF ABOUT $60 MILLION USD Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below